Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3358613 | 0.88 | POLA1 (0.32) | LMNAHTT | |
| SCHEMBL1150166 | 0.83 | LMNA (0.51) | LMNAALDH1A1MAPTSMN1; SMN2TP53 | |
| SCHEMBL1150163 | 0.83 | LMNA (0.51) | LMNAALDH1A1MAPTSMN1; SMN2TP53 | |
| SCHEMBL1685648 | 0.83 | LMNA (0.51) | LMNAALDH1A1MAPTSMN1; SMN2TP53 | |
| SCHEMBL1150168 | 0.83 | LMNA (0.51) | LMNAALDH1A1MAPTSMN1; SMN2TP53 | |
| SCHEMBL1685649 | 0.83 | LMNA (0.51) | LMNAALDH1A1MAPTSMN1; SMN2TP53 | |
| SCHEMBL1685655 | 0.81 | LMNA (0.46) | LMNAALDH1A1MAPTMGAMGAA | |
| SCHEMBL20815360 | 0.80 | LMNA (0.45) | LMNAALDH1A1MGAMGAASI | |
| SCHEMBL1685659 | 0.79 | LMNA (0.44) | LMNAALDH1A1MAPTTP53TSHR | |
| SCHEMBL2127418 | 0.77 | LMNA (0.51) | LMNAALDH1A1MAPTMGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709651-B2 | asymmetriccomplex of copper(I) trifluoromethanesulfonate and 1,1-bis[2-[(4S)-(tert-butyl)-oxazoline]]cyclopropane is added to 3-methyl-2-butenyl acetate and ethyl diazoacetate using dichloroethane solvent to effect reaction to produce ethyl 3,3-dimethyl-2-(acetoxymethyl)cyclopropanecarboxylate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-05-04 | — | — | US | disclosed |
| US-20070032659-A1 | Process for producing optically active cyclopropane compound and asymmetric copper complex for use in the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1674445-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE COMPOUND AND ASYMMETRIC COPPER COMPLEX FOR USE IN THE SAME | Sumitomo Chemical Company, Limited (JP) | 2006-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032659-A1 | Process for producing optically active cyclopropane compound and asymmetric copper complex for use in the same | CBR3, AOC3, CBR1 | LMNA 4237/4885ALDH1A1 185/4885MAPT 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.